Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Paul G. Richardson; Albert Oriol; Meral Beksaç; Anna Marina Liberati; Mónica Galli; Fredrik Schjesvold; Jindriska Lindsay; Katja Weisel; Darrell White; Thierry Façon; Jesús F. San Miguel; Kazutaka Sunami; Peter O’Gorman; Pieter Sonneveld; Paweł Robak; С. В. Семочкин; Steve Schey; Xin Yu; Thomas Doerr; Amine Bensmaine; Tsvetan Biyukov; Teresa Peluso; Mohamed H. Zaki; Kenneth Anderson; Meletios A Dimopoulos; Niels Abildgaard; Howard L. Adler; Fevzi Altuntaş; Olga Meltem Akay; Bipinkumar Amin; Αchilles Anagnostopoulos; Larry D. Anderson; Pekka Anttila; Carla Araujo; Carlos Arce‐Lara; Yıldız Aydın; Supratik Basu; Ramakrishna Battini; Thaddeus Beeker; Lotfi Benboubker; Dina Ben‐Yehuda; Joan Bladé; Igor Wolfgang Blau; Ralph V. Boccia; Lillian Burke; Peter D. Byeff; Nicola Cascavilla; Michèle Cavo; Andrew Chantry; Yen Charles; Arvind Chaudhry; Alessandro Corso; Mark Coyne; Felipe de Arriba; Sosana Delimpasi; P. Desjardins; Binod Dhakal; Paolo Di Bartolomeo; Francesco Di Raimondo; Jan Dürig; Monika Engelhardt; Martine Escoffre‐Barbe; Graça Esteves; Max Flogegård; Nashat Gabrail; Barbara Gamberi; Mitchell Garrison; Julie Gay; Heinz Gisslinger; Hartmut Goldschmidt; Cristina Gonçalves; Laurent Gressot; Sebastian Grosicki; Wahid T. Hanna; Patrick Hayden; Maria Manuela Henriques Bernardo; Róbert Hermann; Viran Holden; Kirsti Honkalehto; Marianne Huben; John Huffman; Hannah Hunter; Marek Hus; Madan Jagasia; Sundar Jagganath; Murali Janakiram; Ishmael Jaiyesimi; Matthew Jenner; Cristina João; Peter Johnson; Artur Jurcyszyn; Sevgi Kalayoğlu Beşışık; Suman Kambhampati; Abraham S. Kanate; Ìhsan Karadoǧan; Ali Khojasteh; Dean Kirkel; Mieczysław Komarnicki; Maria‐Theresa Krauth; Phillip Kuriakose

doi:10.1016/s1470-2045(19)30152-4

Article2015

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

Meletios A Dimopoulos, Philippe Moreau, Antonio Palumbo, Douglas Joshua, Luděk Pour, Roman Hájek, Thierry Façon, Heinz Ludwig, Albert Oriol, Hartmut Goldschmidt, Laura Rosiñol, Jan Štraub, Aleksandr Suvorov, Carla Araujo, Elena Rimashevskaya, Tomáš Pika, Gianluca Gaïdano, Katja Weisel, Vesselina Goranova‐Marinova, Anthony P. Schwarer, Leonard Minuk, Tamás Masszi, Ievgenii Karamanesht, Massimo Offidani, Vânia Hungria, Andrew Spencer, Robert Z. Orlowski, Heidi H. Gillenwater, Nehal Mohamed, Shibao Feng, Wee Joo Chng

Article2021

Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial

Meletios A Dimopoulos, Evangelos Terpos, Mario Boccadoro, Sosana Delimpasi, Meral Beksaç, Eirini Katodritou, Philippe Moreau, Luca Baldini, Argiris Symeonidis, Jelena Bila, Albert Oriol, María‐Victoria Mateos, Hermann Einsele, Ioannis Orfanidis, Tahamtan Ahmadi, Jon Ukropec, Tobias Kampfenkel, Jordan M. Schecter, Yanping Qiu, Himal Amin, Jessica Vermeulen,

Article2013

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

Jesús F. San Miguel, Katja Weisel, Philippe Moreau, Martha Q. Lacy, Kevin Song, Michel Delforge, Lionel Karlin, Hartmut Goldschmidt, Anne Banos, Albert Oriol, Adrían Alegre, Christine Chen, Michèle Cavo, Laurent Garderet, Valentina Ivanova, Joaquín Martínez‐López, Andrew R. Belch, Antonio Palumbo, Stephen Schey, Pieter Sonneveld, Xin Yu, Lars Sternås,

Article2020

Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse

Meletios A Dimopoulos, Katja Weisel, Philippe Moreau, Larry D. Anderson, Darrell White, Jesús F. San Miguel, Pieter Sonneveld, Monika Engelhardt, Matthew Jenner, Alessandro Corso, Jan Dürig, Michel Pavic, Morten Salomo, Eva Casal, Shankar Srinivasan, Xin Yu, Tuong Vi Nguyen, Tsvetan Biyukov, Teresa Peluso, Paul G. Richardson

Article2016

An open-label, randomised phase 3 study of daratumumab, lenalidomide, and dexamethasone (DRd) versus lenalidomide and dexamethasone (Rd) in relapsed or refractory multiple myeloma (RRMM): POLLUX

Meletios A Dimopoulos, Albert Oriol, Hareth Nahi, Jesús F. San Miguel, NJ Bahlis, Neil Rabin, Robert Z. Orlowski, M. Komarnicki, Kazuyuki Suzuki, Trine Lindhardt Plesner

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Discussion(0)

Related publications

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse

An open-label, randomised phase 3 study of daratumumab, lenalidomide, and dexamethasone (DRd) versus lenalidomide and dexamethasone (Rd) in relapsed or refractory multiple myeloma (RRMM): POLLUX